Sensei Biotherapeutics (NASDAQ:SNSE) Announces Earnings Results

Sensei Biotherapeutics (NASDAQ:SNSE) released its quarterly earnings data on Tuesday. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01, Yahoo Finance reports.

Sensei Biotherapeutics Stock Down 5.8 %

NASDAQ:SNSE traded down $0.04 on Wednesday, hitting $0.61. 11,478 shares of the company’s stock traded hands, compared to its average volume of 132,850. The company has a market cap of $15.35 million, a PE ratio of -0.54 and a beta of 0.03. The firm has a 50-day moving average price of $0.67 and a 200-day moving average price of $0.91. Sensei Biotherapeutics has a 1 year low of $0.51 and a 1 year high of $1.94. The company has a current ratio of 12.07, a quick ratio of 12.07 and a debt-to-equity ratio of 0.01.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on SNSE. Stephens reiterated an “overweight” rating and set a $5.00 price target on shares of Sensei Biotherapeutics in a research report on Friday, May 24th. Citigroup reaffirmed a “buy” rating and issued a $4.00 target price on shares of Sensei Biotherapeutics in a report on Monday, June 3rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of Sensei Biotherapeutics in a report on Wednesday.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.